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Vitro and Promote Marrow Engraftment In Vivo 
By William J. Murphy, Jonathan R. Keller, Christie L. Harrison, Howard A. Young, and Dan L. Longo 
Purified natural killer  (NK) cells were obtained from mice 
with severe combined immune deficiency (SCID) to  ascertain 
their effect on hematopoiesis. When activated and propa- 
gated with recombinant human interleukin-2 (rhlL-2) in  vitro, 
SCID spleen cells maintained a phenotypic and lytic spec- 
trum  consistent with a pure population of activated NK cells. 
When added with syngeneic bone marrow cells (BMC) in  soft 
agar,  the activated  NK cells could support  hematopoietic 
growth in  vitro without the addition  of exogenous hematopoi- 
etic growth factors.  However, when syngeneic BMC were 
added  along  with cytokines  to produce  optimal  growth 
conditions, the addition of NK cells was then inhibitory for 
hematopoietic colony formation. Antibodies to interferon7 
(1FN-y) partially reversed the inhibitory effects. Supernatants 
from the NK-cell cultures could also exert these effects on 
hematopoiesis, although to a lesser extent. Analysis of the 
NK cell RNA demonstrated that activated NK cells express 
genes for hematopoietic growth factors such as granulocyte- 
ATURAL KILLER (NK) cells are lymphoid cells that  N are responsible for mediating a variety of  immuno- 
logic and homeostatic functions. NK cells have the ability to 
lyse certain transformed cell lines and virally infected cells 
in  a  non-major  histocompatibility  complex  (MHC)-re- 
stricted manner.’  However, NK cells are also reported to 
regulate B-cell function.* Additionally, NK cells have been 
shown to mediate the rejection of  bone marrow allografts, 
but not solid tissue allografts, in lethally irradiated mice.3 
Because NK cells can reject incompatible bone marrow 
cells (BMC), it has been postulated that NKcells also play a 
role in the regulation of  hematopoiesis.’ The majority of 
previous studies on NK cells, using both in vitro and in vivo 
assays, have suggested that they primarily exert a negative 
However, there have also been reports demon- 
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macrophage colony-stimulating  factor  (GM-CSF),  granulo- 
cyte CSF (G-CSF), and IL-lp. The NK cells were also found to 
express IFN7, transforming growth factor-pl (TGF-pl), and 
tumor necrosis factor-a (TNF-a) mRNA. Analysis of the NK- 
cell supernatants using factor-dependent myeloid  progenitor 
cell lines showed that the NK cells were producing G-CSF 
and growth-promoting activity that could not be attributed 
to  IL-1, IL-3, IL-4, IL-5, IL-6, GM-CSF, G-CSF, macrophage CSF 
(M-CSF), or stem cell factor. The transfer of activated NK cells 
with BMC into lethally irradiated syngeneic mice resulted in 
greater  BMC  engraftment  in the  recipients.  Thus,  these 
results using a pure population of activated NK cells indicate 
that when activated,  these cells can produce a variety  of 
growth factors for hematopoiesis and exert significant hema- 
topoietic growth-promoting effects in  vivo. 
This is a US government work. There are no restrictions on 
its use. 
strating  that  purified  recombinant  human  interleukin-2 
(rhIL-2)-activated  NK cells were capable of  producing the 
hematopoietic growth factor, granulocyte-macrophage col- 
ony-stimulating factor (GM-CSF).8,9  A major problem  in 
the reconciliation of  these findings has been the difficulty in 
obtaining pure populations of  NK cells to assay. NK cells 
constitute a relatively small percentage of  lymphoid cells 
and  NK-cell  preparations  often  contain  contaminating 
populations of  T cells. Although NK cells are similar to T 
cells morphologically and share certain  surface markers, 
murine NK cells are negative for the T-cell markers CD3, 
CD4, and CD8.l  Additionally, the few  markers that NK 
cells express have also been found on other cell types,1° 
which makes cell depletion experiments difficult to inter- 
 ret.^ We  circumvented  this  problem  by  obtaining  pure 
populations of  NK cells through the use of mice with severe 
combined immune deficiency (SCID), which lack T or B 
cells, yet have normal NK cells and NK cell function.”  We 
report here that purified  rhIL-2-activated  NK  cells ob- 
tained  from  SCID mice  exhibit  dual properties  in  the 
regulation of  hematopoiesis in vitro. We find that activated 
NK cells can inhibit colony-forming unit-culture (CFU-c) 
formation  when  cultured  with  BMC  and  hematopoietic 
growth factors in soft agar assays. This inhibition is medi- 
ated at  least  in  part  by  interferon-y  (IFN-y).  However, 
activated  NK  cells  cultured  with  BMC  under  limiting 
conditions,  in  the  absence  of  exogenous  hematopoietic 
growth factors, could support the growth of  hematopoietic 
colonies in vitro. We report here that NK cells are capable 
of  producing a variety of  factors that affect hematopoietic 
cell growth,  including a  potentially  novel  hematopoietic 
growth factor. Additionally, the adoptive transfer of  these 
activated NK cells with BMC resulted in greater hematopoi- 
etic engraftment in lethally irradiated syngeneic recipients. 
Thus, NK cells do not function exclusively as inhibitors of 
hematopoiesis; their hematologic effects are bifunctional. It 
is  possible  that  their  functions  might  be  exploitable  in 
certain clinical settings. 
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MATERIALS AND METHODS 
BALB/cJ  (H-2d/Hh-ld)  and  C.B-17 scidlscid  (SCID, 
H-2d/Hh-ld)  were obtained from the Animal Production Area, 
National Cancer Institute (NC1)-Frederick Cancer Research and 
Development Center (FCRDC), Frederick, MD. SCID mice were 
kept in specific pathogen-free conditions  until use. Mice were used 
at 8 to 12 weeks of  age. SCID mice were given neomycin sulfate 
(Biosol liquid; Upjohn, Kalamazoo, MI), 200 mg (1 mL), in 500 mL 
of tap water. 
NK  cells were 
prepared from the spleens of  6- to 8-week-old SCID mice in  a 
procedure described previously.12 The spleen cell suspension was 
cultured in 500 U/mL of rhIL-2 (a gift from Hoffmann-LaRoche, 
Nutley, NJ) for 7 to 10 days before use. Cultures were fed every 4 to 
5 days with 500 U/mL of  rhIL-2 until use. For marker analysis, 
cultured cells  were incubated  with the appropriate primary antibod- 
ies, as previously described."  The primary antibodies used were 
2Cll (anti-CD3), anti-Lyt-2  (anti-CD8), anti-L3T4 (anti-CD4), 
2.462 (anti-Fc receptor), 30-H12 (anti-Thyl.2), 8C5 (a marker on 
murine   granulocyte^),'^  B220  (RA3-6B2), Mac-1,  and  5E6  (a 
marker found on a subpopulation of  NK  cells).14 Anti-L3T4 and 
anti-Lyt-2 were obtained from Becton Dickinson (Mountain View, 
CA). The 2Cl1, 30-H12, 2.402, Mac-1, 8C5, and B220 antibodies 
were generous gifts from Dr James Kenny, Program Resources 
Inc/DynCorp, NCI-FCRDC. All primary antibodies were directly 
fluorescein isothiocyanate (F1TC)-labeled or biotin-conjugated. 
Cells were then fixed in 1% paraformaldehyde and analyzed on  an 
EPICS 753 flow cytometer (Coulter, Hialeah, FL). 
Spleen cells or BMC cells from 
mice were washed and resuspended in  Iscove's  modified Dulbec- 
CO'S  medium (IMDM) with  10% fetal bovine  serum, 1% L-glu- 
tamine, and antibiotics (complete IMDM). A quantity of  5 X  lo4 
BMC or 5 x 105  spleen cells were plated in 0.3% bactoagar (Difco 
Laboratories, Detroit,  MI)  in  35-mm  Lux  petri  dishes  (Miles 
Laboratories, Naperville, IL). Colony formation was stimulated in 
some cases with predetermined optimal doses of growth-promoting 
cytokines such as rhIL-2 (500 U/mL) and purified murine IL-3 (10 
ng/mL) supplied by  the Biological Response Modifiers Program 
repository and purified recombinant murine GM-CSF at 10 ng/mL 
(AMGEN, Thousand Oaks, CA). Plates were incubated at 37°C for 
7 days. The plates were scored for colonies, where greater than 50 
cells constituted  a  colony.  The  anti-mouse interferon  (IFN-v) 
monoclonal antibody was a rat IgGl (Lee Biomolecular, San Diego, 
CA) used at a 1:lOO dilution. In bone marrow transplant (BMT) 
studies, one-third spleen equivalent was plated 7 days after BMC 
transfer. 
Total  cellular  RNA  was  isolated  from  cell 
preparations by a single-step phenol/chloroform extraction proce- 
dure using RNAsol (Cinna Biotecx, Friendswood, TX)  as reported 
e1~ewhere.l~  Total  cytoplasmic RNA  (10  pg  per  sample) was 
size-fractioned on a formaldehyde-denaturing 0.8%  agarose gel 
and transferred to Nytran (Schleicher and Schuell, Keene, NH). 
After W cross-linking (Stratalinker, Stratagene, LaJolla, CA), 
blots were hybridized in NyloHybe (Digene, Silver Spring, MD) to 
32P-labeled  cDNA probes prepared by  random priming using  a 
commercially  available kit (Pharmacia,  Piscataway, NJ). Hybridiza- 
tion was for 24 to 36 hours at 42°C. After hybridization, the blots 
were washed for 10 minutes at room temperature in 2X standard 
saline citrate (SSC) 0.1% sodium dodecyl sulfate (SDS), followed 
by  a 20-minute wash  at 65°C  in  0.02X  SSC, 0.01%  SDS. After 
hybridization with one probe, the blots were stripped by  placing in 
boiling 0.02X SSC, 0.01%  SDS for 20  minutes. Blots were then 
placed in hybridization buffer for 1  to 2 hours and the next probe 
was added. All cDNA probes had a specific  activity of 2 to 8 x 
Mice. 
Propagation  of  NK cells  and  marker  anatysis. 
Assay for in vitro hematopoiesis. 
RNA  anabsis. 
cpm/pg  and  all hybridizations were  performed with  1 x 
cpm/mL.  Blots  were  exposed  to  Kodak  X-OMAT  x-ray  film 
(Eastman Kodak, Rochester, NY)  for 24 to 72 hours at -70°C. 
One  microgram of  total 
cellular RNA was first transcribed with Moloney Leukemia Virus 
Reverse  transcriptase  (BRL,  Gaithersburg, MD)  in  a  100-pL 
reaction for 15 minutes at 42°C according to the manufacturer's 
instructions. The reaction was then heated to 99°C for 5 minutes 
and then cooled to 5°C for 5 minutes. Polymerase chain reaction 
(PCR)  was  then  performed  using  2  U  of  Perkin-Elmer Taq 
polymerase (Norwalk, CT)  and mouse IL-3 primers (Clontech, 
Palo Alto, CA) according to the manufacturers' recommendations 
for 30 cycles, with  each cycle consisting of  1 minute at 94"C, 2 
minutes at 55"C, and 3 minutes at 72°C. At the end of  30 cycles, the 
reaction was completed by  incubating at 72°C for 7 minutes. Ten 
microliters of the reaction was then run on  a 0.8% agarose gel, the 
gel then denatured for 20 minutes in 0.4N NaOH, 1.5 mol/L NaCl, 
neutralized for 20 minutes in 1  mol/L Tris, pH 7.4, 1  mol/L NaCI, 
and transferred to Nytran in 1OX SSC for 3 hours. The membrane 
was then hybridized to a 32P-labeled  IL-3 cDNA as described above. 
Murine  IFN-y,  IL-2,  and  IL-4  cDNAs were 
obtained from DNAX Research Institute (Palo Alto, CA); murine 
GM-CSF cDNA from Dr A.W.  Burgess (Ludwig Institute, Victo- 
ria, Australia); murine granulocyte CSF (G-CSF) cDNA from Dr 
Shigekazu Nagata  (Osaka  Biosciences, Osaka, Japan);  murine 
tumor necrosis factor-a (TNF-a) cDNA from Dr Anthony Cerami 
(Rockefeller University, New  York, NY);  murine IL-la cDNA 
from Dr Peter Lomedico (Hohann-LaRoche, Nutley, NJ); mu- 
rine IL-lp from Dupont deNemours (Wilmington, DE); murine 
IL-3 and IL-6 cDNAs from Dr Stephen Clark (Genetics Institute, 
Cambridge, MA); murine IL-5 cDNA from the American Type 
Culture Collection (Rockville, MD); murine IL-7 cDNA from Dr 
Steven Gillis (Immunex, Seattle, WA); murine transforming  growth 
factor-pl  (TGF-PI) cDNA from Dr  Rik Derynck (Genentech, 
South San Francisco, CA); mouse perforin cDNA from Dr KO 
Okumura (Juntendo University, Tokyo, Japan); human IL-2 recep- 
tor p-chain cDNA from Dr Warren Leonard (National Institute of 
Child  Health  and  Human  Development, Bethesda, MD);  and 
murine IL-2 receptor a-chain cDNA from Dr Jim Miller (Univer- 
sity of Chicago, Chicago, IL). 
The hematopoietic progenitor cell lines 32D-CL.23 
and 32D-CL.3 were developed in murine long-term bone marrow 
cultures.16  The NFS/Nl.M6 (MC-6) cell line17  was provided by Dr 
Douglas Williams (Immunex). These cell lines are IL-3-dependent 
and were maintained in complete RPMI 1640 medium plus 20% 
WEHI-conditioned medium as a source of  IL-3. Briefly, the cell 
lines were washed  twice  in  serum-free RPMI  1640 media and 
pelleted by  centrifugation. The cells were then  resuspended in 
complete RPMI 1640 medium (5% fetal calf serum, glutamine, and 
penicillin/streptomycin)  and plated at a density of 5,000 cells in 100 
pL in 96-well microtiter plates (Costar, Cambridge, MA). Some 
wells  also  contained  25%  NK cell  supernatants,  which  were 
collected after the NK  cells were in culture with IL-2 for 7 to 10 
days.  Recombinant murine IL-3 was  purchased from  Promega 
(Rockyhill, NJ),  and  recombinant murine IL-4 from Genzyme 
(Cambridge, MA). The cells were then incubated for 48 hours at 
37T, 5% CO2, and pulsed with 1 FCi [3H]thymidine (TdR) (6.7 
Ci/mmol; New England Nuclear, Boston, MA) for the last 6 hours. 
The plates were then harvested with a multiple sample harvester 
on a glass filter. Individual filters were placed in 2 mL of  PCS 
scintillation fluid (Amersham, Arlington Heights, IL) and radioac- 
tivity was assessed by liquid scintillation counting. 
Recipient  mice  were 
exposed to 13'Cs  gamma irradiation source. BALB/c mice received 
PoZymerase  chain  reaction  analysis. 
cDNA probes. 
Cell lines. 
Irradiation  and  pretreatment  of mice. 
For personal use only. on November 6, 2014.  by guest    www.bloodjournal.org From 672  MURPHY ET AL 
800 cGy total irradiation. Mice in some groups received 2  x  IO7 
SCID NK cells that were in culture with rhlL-2 for 7 to 10 days. 
The NK cells were injected with  1  x  1oh BALB/c BMC intrave- 
nously. The mice then received 50.OOO  rhlL-2 in 0.5 mL phosphate- 
buffered saline (PBS) intraperitoneally once a day for 3 days after 
BMC transfer. Mice in other groups either received  BMC alone, 
BMC with  rhlL-2, BMC with  2 x  IO7 BALB/c spleen cells and 
rhlL-2. or irradiation alone.  In  groups receiving  irradiated NK 
cells,  the NK  cells were  exposed  to  2.00 cGy 3 hours hefore 
transfer. After 7 days, a soft-agar colony assay was performed on 
the spleens of  the recipients to determine hematopoietic progeni- 
tor cell content. For  analysis of  the peripheral hlood, blood was 
collected from mice via  the lateral tail vein, using EDTA as an 
anticoagulant. Complete blood cell counts were performed with a 
Coulter counter (Hialeah, FL) and differential cell counts were 
performed by microscopic examination of Wright's stained periph- 
eral blood  smears (Met  Path,  Rockville,  MD). All experiments 
consisted of  three to four mice per group with  a representative 
experiment being shown. Student's r-test was performed to deter- 
mine whether the values differed  significantly at the (/'  < .Wl) 
level. 
RESULTS 
NK cells  can  be  propagated  in  vitro-and  maintain  a 
homogeneous  phenotype.  To obtain  purc  homogeneous 
populations of  NK cells to assay, SCID mice were used.Ix 
SCID mice have a defect in their rccombinasc system and 
cannot  successfully rearrange  their  T-cell rcceptor  or Ig 
genes.Iy As  a result, SCID mice have no dctcctable T or B 
cells; however, they  have  normal  NK cells and  NK-cell 
function."  SCID spleen cells were cultured with rhIL-2 for 
7 to 10 days. This has been demonstrated to produce a purc 
population of  activated NK cells with respect to phenotype 
and  function.'?  Thc cells obtained  in  this  manncr  wcrc 
positive for classical NK markers such as Thy-l (present on 
activatcd NK c~lls),~  FcR, and SE6  (present on a subpopu- 
lation of  NK cells)IJ (Fig  1).  The cclls wcrc also greater 
than 9S%  positive for asialo GMI (data not  shown). The 
cells wcrc  negative for CD3, CD4, and  CDX;  thc macro- 
phage marker,  MAC-I; the granulocyte markcr, XCS:  and 
thc B-cell marker, B220 (Fig I). Thcse cells also maintained 
a  lytic  spectrum  consistent  with  a  purc  population  of 
activatcd NK cells (data not shown).'&  The NK cells wcrc 
then  used  in a soft-agar  hematopoietic colony formation 
assay to dcterminc thc role of  these cells in hcmatopoicsis. 
Activated  NK  cells  can  sripporr  hemntopoiesis  in  1.itt-o. 
When activatcd NK cells or BMC arc placed  in soft agar 
alone, no  hematopoietic colonies  are formed  (Table  I). 
Howcvcr, whcn activatcd NK cells arc addcd with the RMC 
at a  1:l ratio, hcmatopoictic colonics appeared. Addition- 
ally, culture  supernatants obtained  from  the  propagated 
NK cells could also support the growth of BMC, although to 
a much lesser extent. Howcvcr, the addition of rhlL-2 alone 
had no cffcct on colony formation. Phenotypic analysis of 
the colonies  indicated  that  they wcrc  of  myeloid  origin, 
consisting of  macrophage,  granulocyte,  and  granulocyte/ 
macrophage-type  colonies.  Intcrcstingly,  whcn  NK  cells 
wcre addcd together with BMC and CSFs such as IL-3 and 
GM-CSF, a significant dcgrcc of  inhibition (62%) of colony 
growth was observed (Table I). Thus, NK cells appear to be 
bidircctional regulators of hematopoiesis: whcn given alone 
with BMC, they can promote colony formation, but they can 
a.  I 
0. 
NRIg  CD4  CD3 
-e,-y  I.  13.  ,  t4.  '58, '6. 
___-I  A_-  -0  F 
2 2 
E 
1; 
D 
0-  0 
--:  0.4%  0.1 %  L' 
In:  .- 
-0 
v- 
4 
Thy-1  FCR  8220 
Fig 1.  Phenotype of SCID spleen cells after culture  with rhlL2for 7 to 10 days as determined  through flow cytometric analysis as described in 
Materials and Methods. 
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Table 1.  rhlL-24ctivated  NK Cells and Hematopoiesis In Vitro 
Treatment.  CFU-ct 
~  ~~ 
BMC alone 
EMC with cytokines 
NK  cells alone 
EMC with rhlL-2 
EMC with cytokines and rhlL-2 
BMC with NK-cell supernatant 
EMC with NK  cells (1:l) 
EMC with cvtokines and NK cells (1:ll 
or0 
128 2  26 
Or0 
020 
110 2 4 
220 
17 2 6 
49 2  1 
Data representative of four experiments. 
*Cultures were supplemented with IL-3 (10 nglmL) and GM-CSF (10 
nglmL), rhlL-2 (500 UlmL), NK-cell supernatant (0.2 mL); or 7 to 10-day 
rhlL-2-cultured  SClD spleen cells containing at least 95% NK  cells were 
plated at a 1:l  ratio with BMC (2 x  105) in 100 pL rhlL-2-containing 
media (500  UlmL). 
tSClD BMC  were plated in soft agar  according to the  procedure 
described in Materials and Methods. The plates were scored for colony 
growth  after 7 days. 
Fig 2.  Northem blot analysis of cultured NK cells. 
SClD spleen cells were cultured  with rhlL-2  for 7 to  10 
days.  RNA was  prepared from the cells,  run on a 
formaldehyde agarose  gel,  transferred to a Nylon 
membrane,  and hybridized with probes of  various 
cytokines as described in  Materials and Methods. 
also inhibit hematopoietic cell growth driven by  exoge- 
nously added hematopoietic growth factors. 
NK  cells transcribegenes  fora variety of cytokines capable of 
exerring  diverse  effects  on  hematopoiesis.  To  determine 
what cytokines activated NK cells were capable of  produc- 
ing, we  first examined mRNA expression. As shown in Fig 
2,  mRNA  for a number of  different cytokine genes was 
detected  when  total  cellular  RNA  from  the  rhIL-2- 
activated NK cells was analyzed. Specific hybridization was 
observed with probes for IL-lp, IL-6, G-CSF, GM-CSF, 
TNF-a, IFN-y, TGF-P1, and both the rhlL-2 receptor a- 
and P-chains (Fig 2), as well as perforin, a protein involved 
in cell killing (data not shown). In contrast, no hybridization 
was observed with probes for IL-la, IL-2, IL-3, IL-4, IL-5, 
or M-CSF (data not shown). To be certain that IL-3 mRNA 
was not present at levels below the threshold of  detection, 
amplification of  IL-3 mRNA was attempted by  PCR analy- 
sis. No IL-3 mRNA was detected (Fig 3), even though it was 
found when examining rhIL-2-activated  splenocytes from 
G-CSF  GM-CSF  IL-18  IL-6 
6 
1FN-y  TG FB 
-18s 
-18s  -18s 
U 
-28s  -28s 
TNFa 
-  28s 
IL-2Ra  IL-PRP 
c  -- 
I -28s  -  28s 
1 
II 
-  18s  -  18s 
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500 bp- 
AB 
Fig 3.  Northern blot analysis 
after PCR  amplification of  RNA 
from cultured SClD  NK cells. SClD 
and  BALB/c  mice  splenocytes 
were placed  in culture with rhlL-2 
for 7 to 10 days. RNA was ampli- 
fied using the PCR  and then hy- 
bridized with  cDNA  probe for 
murine  IL-3 as described in Mate- 
rials and Methods. Lane A is of 
the SClD NK cells, and lane B is 
of BALB/c splenocytes  that were 
cultured  with rhlL-2  for 7 days. 
BALB/c mice. Thus,  activated NK  cells transcribe mRNA 
for a variety of cytokines that are capable of both inhibiting 
(IFN-y, TGF-B, TNF-a) and stimulating (IL-lB, G-CSF, 
GM-CSF) hematopoiesis. 
Supematants from NK-cell cultures support the growth of 
factor-dependent hematopoietic progenitor cell  lines and a- 
hibit potentially novel growth factor activiy.  To determine 
what  factors were  present  in  the  conditioned  medium 
obtained  from  the  cultured  IL-2-stimulated  NK  cells, 
supernatants were examined for growth-promoting activity 
on factor-dependent myeloid cell lines. A description of the 
factors to which the different cell lines respond is given in 
Table 2.  NK-cell supernatants induced the proliferation of 
32D-CL.23 and 32D-CL.3 cell lines, but not MC-6 (Table 3) 
and  FDC-P1  lines  (data  not  shown)  as  measured  by 
[3H]TdR  incorporation. In agreement with PCR and North- 
ern blot data, the supernatants did not contain IL-3 or IL-4 
activity, as indicated by  the lack of proliferation induced on 
MC-6  and  FDC-P1 cell  lines. Additionally, because the 
supernatants do not  contain  IL-3 and  yet  promote the 
growth of  32D-CL.3 cells,  this suggests that the superna- 
tants contain G-CSF. No neutralizing antibody to murine 
G-CSF is available to confirm this result, although such a 
conclusion is also in  agreement with  the  Northern  blot 
analysis, which  demonstrates that activated NK  cells pro- 
duce  G-CSF mRNA  (Fig 2).  Interestingly, the  NK-cell 
supernatants also induced the proliferation of  32D-CL.23, 
which  have been reported to respond to IL-3 or IL-4, but 
not to other CSFs.16 In addition, antibodies  to IL-3 and IL-4 
did not block the proliferation of 32D-CL.23 induced by the 
Table 2 Profile of Factor Responses  of Hematopoietic  Progenitor 
Cell Lines 
11-3  GM-CSF  G-CSF  M-CSF  IL-4  IL-5  IL-6  SCF 
MC-6  +-  -  -  +--+ 
32D-CL.3  +  -  + 
32D-CL.23  +  - 
FDC-P1  +  -  -  -  +--  -+ 
-  ---- 
-  -  +--- 
NK-cell supernatants, suggesting that the proliferation was 
not due to IL-3 or IL-4 (data not shown). This is also in 
agreement with the lack of  an effect of  the supernatants on 
MC-6 cell line proliferation, which would detect the pres- 
ence of  IL-3 or IL-4. The lack of proliferation of MC-6 cells 
in response to the supernatants also indicates that the NK 
cells are not producing the c-kit ligand or stem cell factor 
(SCF).  Thus, taken  together,  these  results suggest that 
there may be a novel hematopoietic growth factor produced 
by  the  NK cells responsible for the proliferation of  the 
32D-CL.23  cell  line.  Analysis  of  various  other  cloned 
growth factors (IL-1, GM-CSF, G-CSF, TNF) also failed to 
induce the proliferation of  32D-CL.23,  when either given 
alone or in combination (data not shown). Further experi- 
ments will  be  required  to determine the  nature of  this 
activity to ascertain if it is due to a novel  growth  factor 
produced by  the NK cells. 
Activated  NK  cells produce  IFN-y,  which  can  inhibit 
hematopoiesis in  vitro.  Northern  blot  analysis had  indi- 
cated that NK cells could produce IFN-y, and we wanted to 
determine  if  this was  responsible for the  hematopoietic 
suppression seen in vitro. Previous reports have also indi- 
cated  that  NK cells can  produce  IFN-y, which  can  be 
inhibitory  for  hematopoiesis.4 Therefore,  to  examine 
whether  IFN-y could  be  contributing to  colony  growth 
inhibition when  NK cells were placed with  BMC  in the 
absence of  exogenous cytokines, antibodies to IFN-y were 
added  with  NK cells  and  BMC.  The  addition  of  this 
neutralizing antibody resulted in an 87% increase in colony 
formation (Table 4). The presence of IFN-y antibodies also 
significantly increased colony formation supported by  the 
NK-cell supernatants.  Additionally, the antibodies to IFN-y 
could abrogate the NK  cell-mediated  inhibition of  colony 
formation  when  the  BMC  were  placed  with  IG3 and 
GM-CSF. NK cells plated  in agar with either exogenous 
hematopoietic growth factors or with anti-IFN-y  did not 
give rise to colony formation. Thus, activated NK cells can 
produce hematopoietic growth factors that support BMC 
growth in vitro and their effect can be enhanced through 
the neutralization of  inhibitory cytokines, such as IFN-y, 
which are also produced. Protein analysis of  the superna- 
tants using various bioassays also demonstrated the pres- 
ence of  IL-lB, IL-6,  and  IFN-y (data not  shown).  The 
presence of TGF-p was not assayed for at the present time. 
Thus,  although  NK  cells  can  produce  factors that  are 
inhibitory for hematopoiesis, the demonstration that when 
NK cells are placed with BMC alone they can support BMC 
growth suggests that the factors they produce which pro- 
mote hematopoiesis  may, under the appropriate conditions, 
provide a stronger net stimulus. 
rhll-2-activated  NK cells can be adoptively transferred and 
promote engraftment of  syngeneic BMC in lethally irradiated 
recipients.  Because the NK cells were shown to be capable 
of  supporting hematopoiesis in vitro, we  wanted to deter- 
mine if these properties could also be transferred in vivo 
using a syngeneic BMT model. BALB/c mice were lethally 
irradiated  and  given  syngeneic  BMC  with  or  without 
activated SCID NKcells. The results (Table  5) demonstrate 
that the administration of  rhIL-2 with BMC did not result 
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Table 3.  Effect of NK  CelCConditioned Medium on  the Proliferation  of  Factor-Dependent Myeloid Cell Lines 
CPM* 
Cell Line  Medium  NK-CMt  IL-3$  IL-4 
MC-6  313 f  43  259 2  62  164,372 f  14,660  68.772  2 2.132 
32D-CL.3  228 2 73  1,035  f  159  13,263  2  1,260  323 f  ai 
32D-CL.23  1,422  f  351  14,419  f  2,409  129,031  f  10,262  26,470  2  1,190 
Results are representative  of three experiments and are the mean 2  SE of three determinations. 
Abbreviation: CPM, counts per minute. 
'Cell  proliferation was determined by [3H]  Tdr incorporation as described in  Materials  and Methods. 
tNK cell-conditioned medium was obtained after SClD spleen cells were cultured with 500 U/mL rhlL-2 for 7 to 10 days. The phenotype of cells 
SIL-3 and IL-4 were used at a concentration of 20 ng/mL and the NK-cell  supernatent was used at 25% in  the proliferation assays. 
present was greater than 95% NK cells as determined by flow cytometry. 
in an enhancement of  marrow engraftment as determined 
by growth in soft agar when the spleens of  the mice were 
analyzed 7 days after BMC transfer. However, the transfer 
of  rhIL-2-activated  NK cells with BMC resulted in signifi- 
cantly (P  < .001) greater colony formation in the recipients 
when  compared  with  mice  receiving  BMC  alone  or in 
combination with rhIL-2. Therefore, the transfer of rhIL-2- 
activated NK  cells with BMC can aid in marrow engraft- 
ment after syngeneic BMT. We then wanted to determine if 
this effect on marrow engraftment was dependent specifi- 
cally on the transfer  of  activated  NK  cells.  In  another 
experiment, BALB/c splenocytes and rhIL-2 were trans- 
ferred with BMC. The transfer of splenocytes plus IL-2 did 
minimally enhance colony formation in the recipients, but 
not  to the extent of  the groups receiving NK cells and 
rhIL-2 (Table 6). Indeed, the effects of  IL-2 plus normal 
spleen were not significantly  greater than the effects of  IL-2 
alone. Additionally,  the transfer  of  irradiated  NK  cells 
failed to improve engraftment, indicating that the NK cells 
were  not  passively  affecting  the  BMC  by  altering  the 
pattern of  stem cell homing to the spleen. The recipients 
receiving only NK cells with rhIL-2 and no BMC did not 
demonstrate significant hematopoietic engraftment and the 
mice  died within  a  time frame  comparable  to the mice 
Table 4.  Role of IFNyand  NK Cells on Hematopoiesis In Vitro 
Treatment'  CFU-ct 
BMC alone  Of0 
NK cells alone  Of0 
BMC with NK cells (0.5: 1)  32f  1 
BMCwith NKcells(1:l)  52 f  2 
BMC with NK cells (1  :I)  and anti-ylFN  97 2 0 
BMC with NK-cell  supernatant  350 
BMC with NK-cell  supernatant  and anti-ylFN  11 f  1 
BMC with cytokines  75 f  4 
BMC with cytokines and NK cells (1:  1) 
BMC with cytokines, NK cells (1: I),  and anti- 
58 2  4 
ylFN  105 * 10 
Data are representative  of three experiments. 
'Cultures  were supplemented with IL-3  (IO  ng/mL) and GM-CSF (IO 
ng/mL), NK-cell  supernatants  (0.2 mL), SClD NK cells obtained by using 
SClD spleen cells cultured with rhlL-2 (500 U/mL) for 10 days, or  100 
neutralizing units of anti-IFN-y.  E:T ratio reflects NK cells: BMC, with 2 
x IO5  BMC being plated. 
tSClD BMC were plated in soft agar according to the procedures 
described in  Materials and Methods and scored for colony growth after 
7 days. 
receiving radiation  alone.  These  data demonstrate that 
cultured  SCID  NK  cells  do  not  themselves  have  the 
potential  to  give  rise  to  hematopoietic  cells  in  mice. 
Analysis of  the peripheral blood indicated that the transfer 
of  activated  NK  cells with  BMC  significantly improved 
platelet  counts by  day 9, resulting in an almost threefold 
increase in platelets (Fig 4). No other hematologic parame- 
ters were significantly affected at this time, although hema- 
tocrit  values were  also  slightly elevated when  compared 
with groups receiving BMC alone (data not shown). Taken 
together, these results support the notion that transfer of 
activated  NK  cells promotes hematopoietic  engraftment 
and improves hematologic parameters after syngeneic BMT 
in mice. 
DISCUSSION 
The data presented here indicate that activated NK cells 
exhibit a dual role in their hematopoietic regulatory abili- 
ties  based  on their  ability  to produce  a  wide  range  of 
cytokines (GM-CSF,  G-CSF,  IL-1P, TNF-a, IFN-y,  and 
TGF-P).  When  BMC  are placed  under  optimal  growth 
conditions (ie, with exogenous cytokines such as IL-3 and 
GM-CSF), the addition of  activated NK cells does indeed 
inhibit  colony formation,  as  has been  demonstrated by 
However, when BMC are placed  in agar under 
limiting  conditions,  the  addition  of  activated  NK  cells 
promotes CFU-C formation to a significant extent. Thus, 
the failure of  other investigators to detect hematopoietic 
growth-promoting factors produced by  NK cells was per- 
Table 5.  Effect of Activated NK Cells After Syngeneic BMT 
Colonies 
Treatment 
(after  irradiation)  Cytokines*  Media 
0  1.3 f  1.5  Of0 
BMC  11  1.2 f  33.9  Of0 
BMC + rhlL-2t  91.8  f  43.8  Of0 
BMC + NK cells + rhlL-2$  235.5 t  13.55  020 
Data are representative of three experiments with three to four mice 
'IL-3  and  GM-CSF  were  added  with  spleen  cells  7  days  after 
tFiftythousand units of rhlL-2 given intraperitoneally days 0,l. and 2. 
*Two  x  107 SClD NK cells given with BMC intravenously on day 0, 
§Values significantly  (P < .001)  greater  than  recipients  receiving 
per group. 
irradiation as described in  Materials and Methods. 
and 50,000  U rhlL-2 given intraperitoneally on days 0,1, and 2. 
either BMC or BMC with rhlL-2. 
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Table 6.  Transfer of Activated NK Cells Is Necessary  To Promote 
BMC Engraftment After Syngeneic BMT 
Treatment* 
(after irradiation) 
Colonies 
Cytokinest  Media 
0  2.0 f  1.5  Of0 
NK cells + rhlL-2  17.5 f  10.0  0 f  0 
BMC  22.0 f  2.5  Of0 
BMC + rhlL-2  64.5 2 15.3$  0 f  0 
BMC + rhlL-2 + NK cells  0 f  0 
BMC + rhlL-2 + irradiated NK cells  0 f  0 
BMC + rhlL-2 + BALB/c spleen cells  0 f  0 
387.0 f  21.85 
71.5 f  31.3 
87.7 2 10.711 
Data are representative of two experiments with six mice per group. 
*Mice ieceiving rhlL-2 received 5 x 104 U intraperitoneally  on days 0, 
1,  and  2.  Mice receiving NK  cells received 2  x  lo7 SCID NK  cells 
intravenously  on day 0. Mice receiving irradiated NK cells received 2 x 
107 irradiated (2,000 cGy) SCID NK cells intravenously on day 0. Mice 
receiving BALBlc splenocytes received 2  x  lo7 BALB/c  splenocytes 
intravenously  on day 0. 
tlL-3  and  GM-CSF  were  added  with  spleen  cells  7  days  after 
irradiation as described in Materials and Methods. 
*Values signficantly greater (P < .001) than recipients  receiving BMC 
alone. 
§Values significantly  greater (P < .001) than recipients not receiving 
NK cells and rhlL-2. 
IlValues significantly  greater (P < .001) than recipients  receiving BMC 
alone, but not significantly  greater than BMC plus rhlL-2. 
haps related in part to the presence of  inhibitory factors 
produced by the NK cells and the use of exogenously added 
hematopoietic  growth  factors  in  the  assay  system. The 
bidirectional  effects  of  NK  cells  in  vitro  reconcile  the 
apparently contradictory reports in the literature concem- 
ing the effects of NK cells on hematopoie~is.~~  By changing 
the  assay  conditions,  opposite  results  can  be  achieved 
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Fig 4.  Peripheral platelet counts (K/mm’)  in mice  9 days after 
syngeneic BMT: average of  three to four  mice per group. BMT is 
described in Materials  and Methods. 
concerning their effect on hematopoietic growth. Addition- 
ally, by using only pure NK cells obtained from SCID mice, 
one can more stringently examine NK-cell properties with- 
out putting them through extensive and possibly incomplete 
purification procedures. 
We  have  demonstrated  that  activated  NK  cells  are 
capable of  secreting  a wide array of  both hematopoietic 
growth-promoting (IL-1P, G-CSF, GM-CSF) and -inhibit- 
ing cytokines (IFN-y, TGF-P, TNF-or), as well as a poten- 
tially novel hematopoietic growth factor. More work needs 
to be performed to characterize this new activity. In our 
studies, we examined whole populations of  SCID NK cells. 
However, subpopulations of  NK cells may exist that exert 
primarily growth-promoting versus growth-inhibiting func- 
tions on hematopoiesis based on the cytokines that they 
produce. Preliminary results suggest that different subsets 
of  NK  cells  that  exert  different  regulatory  effects  on 
hematopoiesis do exist in mice. Isolation of NK-cell subpop- 
ulations that solely promote hematopoietic growth may also 
allow for easier isolation and characterization of  the poten- 
tially novel hematopoietic growth factor(s)  they may pro- 
duce. 
It  is  of  interest  that  G-CSF has not  been  previously 
described  to be produced  by  NK cek8  Human NK-cell 
populations were examined in many of these studies suggest- 
ing that either G-CSF is only produced by murine NK cells 
or, since human NK cells can be heterogenous with regard 
to cell-specific markers,  subpopulations of  NK cells may 
have been unknowingly excluded in those studies. 
Studies using T-cell-depleted bone marrow to reconsti- 
tute human hematopoiesis have suggested that T cells are 
involved in promoting hematopoiesis. The recent character- 
ization of  an immunodeficiency disease which resulted from 
the inability of  the patient’s T cells to transcribe genes for 
rhIL-2, IL-3, IL-4, IL-5, and IFN-y suggests that other cell 
types may contribute to the maintenance of normal hemato- 
poiesis,  since  the patient’s  hematologic  parameters ap- 
peared normaLZ0  It is possible that, under certain circum- 
stances, NK  cells may be involved. For example, the SCID 
mouse completely lacks T cells, is profoundly deficient in 
lymphopoiesis, but is normal in NK-cell function; despite its 
immunologic dysfunction, the SCID mouse exhibits normal 
hematopoiesis?1 
The demonstration that activated NK cells can support 
hematopoiesis  in vivo  also suggests that they may  be of 
clinical use  to promote  hematopoietic engraftment  after 
BMT. The clinically available CSFs have been shown to 
promote erythropoiesis (erythropoietin) and granulopoiesis 
(G-CSF, GM-CSF), but none  has consistently promoted 
thrombopoiesis. Our animal data suggesting that activated 
NK cells may enhance platelet recovery merit testing this 
approach in humans.  Later time point  analysis indicates 
that mice receiving NK cells and rhIL-2 also had acceler- 
ated immune reconstitution.22  This result also suggests that 
the transfer of  activated NK cells with rhIL-2 may be able to 
enhance antitumor effects when autologous BMT is used in 
the treatment of  neoplasia. We have recently found that the 
transfer of  donor-type activated NK cells with BMC into 
lethally irradiated  allogeneic mice also resulted in better 
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marrow engraftment and long-term donor-derived immune 
reconstitution.22 The idea that NK cells may be stimulatory 
for marrow growth is also supported by recent data using a 
rat model in which rhIL-2-activated NK cells supported the 
growth of  syngeneic BMC, but inhibited allogeneic BMC 
growth  in vitro.23 Therefore,  the transfer  of  donor-type 
rhIL-2-activated  NK  cells  after  BMT may  be  able  to 
provide the positive graft-versus-leukemia effects without 
giving rise to graft-versus-host disease in recipients." 
Thus,  activated  NK  cells  are capable  of  producing  a 
variety of  hematopoietic growth factors, including a poten- 
tially novel cytokine, and can be adoptively transferred to 
promote the engraftment of syngeneic  BMC in vivo. Further- 
more, the data presented here suggest that activated NK 
cells  may  be  of  considerable  use  clinically to promote 
hematopoiesis. 
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